Trade Trend

In 2023, Denmark's total export value is 136.39Billion USD, total import value is 126.02Billion USD, Surplus is 10.37Billion USD, and foreign trade dependency is 0.649. In 2023，Denmark's top export products are Medicaments; (not goods of heading no. 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic use, put up in measured doses (incl. those in the form of transdermal admin. systems) or packed for retail sale(15.75Billion USD), None(7.92Billion USD), Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) etc(4.77Billion USD), top export destinations are Germany(18.27Billion USD), None(15.72Billion USD), None(14.52Billion USD). In 2023, Denmark's top import products are Petroleum gases and other gaseous hydrocarbons(8.20Billion USD), Motor cars and other motor vehicles; principally designed for the transport of persons (other than those of heading no. 8702), including station wagons and racing cars(7.05Billion USD), Medicaments; (not goods of heading no. 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic use, put up in measured doses (incl. those in the form of transdermal admin. systems) or packed for retail sale(3.61Billion USD), top import origins are Germany(23.47Billion USD), Sweden(14.49Billion USD), Norway(13.65Billion USD).

Comparing to 2022, Denmark's total export value increased 4.60Billion USD(3.49%) in 2023, this could result from its export increases of products such as None(5.30Billion USD or 202.22%), Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) etc(1.26Billion USD or 35.92%), Swine; live(764.47Million USD or 78.60%) and export increases to countries/economics such as None(5.67Billion USD or 64.04%), Poland(701.19Million USD or 15.06%), United Kingdom(672.50Million USD or 13.59%). Comparing to 2022, Denmark's total import value decreased -2.32Billion USD(-1.81%) in 2023, this could result from its import decreases of products such as Electrical energy(-1.87Billion USD or -57.31%), Lightvessels, firefloats, dredgers, floating cranes, other vessels; the navigability of which is subsidiary to main function; floating docks, floating, submersible drilling, production platforms(-765.23Million USD or -99.50%), Petroleum oils and oils obtained from bituminous minerals; crude(-571.10Million USD or -15.44%), and its import decreases from countries/economies such as China(-2.52Billion USD or -24.99%), Germany(-2.30Billion USD or -8.91%), Sweden(-1.16Billion USD or -7.43%).

Cumulated to first 7 months of 2024, Denmark's total export value is 46.10Billion USD, total import value is 41.79Billion USD, and tradesurplus is 4.31Billion USD. Cumulated to first 7 months of 2024, Denmark's top export products are Commodities not specified according to kind(6.32Billion USD), Medicaments; (not goods of heading no. 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic use, put up in measured doses (incl. those in the form of transdermal admin. systems) or packed for retail sale(5.57Billion USD), Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) etc(1.41Billion USD), and top export destinations are None(6.31Billion USD), None(5.14Billion USD), Germany(4.48Billion USD). Cumulated to first 7 months of 2024, Denmark's top import products are Commodities not specified according to kind(6.32Billion USD), Medicaments; (not goods of heading no. 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic use, put up in measured doses (incl. those in the form of transdermal admin. systems) or packed for retail sale(5.57Billion USD), Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) etc(1.41Billion USD), and top import origins areNone(6.56Billion USD), Germany(5.79Billion USD), Sweden(3.51Billion USD).